Inflammation and nephron loss

• Applicant: Professor Dr. Hans-Joachim Anders
• Subject Area: Nephrology
• Term: from 2017 to 2022
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 326693426

• Final Report Year: 2022

Final Report Abstract

No abstract available

Publications

• Interleukin-1β Inhibition for Chronic Kidney Disease in Obese Mice With Type 2 Diabetes.Front. Immunol., Sec. Alloimmunity and Transplantation, Vol. 10. 2019, 1223.
  Lei, Y., Devarapu, S.K., Motrapu, M., Cohen, C.D., Lindenmeyer, M.T., Moll, S., Kumar, S.V., Anders, H.J.
  
• Mitochondria Permeability Transition versus Necroptosis in Oxalate-Induced AKI. J Am Soc Nephrol. Vol. 30. 2019, Issue 10, pp. 1857-1869.
  Mulay S.R., Honarpisheh M.M., Foresto-Neto O., Shi C., Desai J., Zhao Z.B., Marschner J.A., Popper B., Buhl E.M., Boor P., Linkermann A., Liapis H., Bilyy R., Herrmann M., Romagnani P., Belevich I., Jokitalo E., Becker J.U., Anders H.J.
  
• Crystal Clots as Therapeutic Target in Cholesterol Crystal Embolism. Circulation Research, Vol. 126. 2020, Issue 8: e37-e52.
  Shi C., Kim T., Steiger S., Mulay S.R., Klinkhammer B.M., Bäuerle T., Melica M.E., Romagnani ., Möckel D., Baues M., Mammadova-Bach E., Yang L., Brouns S.L., Heemskerk J.W., Braun A., Lammers T., Boor P., Anders H.J.
  
• Drug testing for residual progression of diabetic kidney disease in mice beyond therapy with metformin, ramipril, and empagliflozin.Journal of the American Society of Nephrology, Vol. 31. 2020, Issue 8, pp. 1729-1745.
  Motrapu M., Swiderska M.K., Mesas I., Marschner J.A., Lei Y., Velenzuela L.M., Fu J., Lee K., Angelotti M.L., Antonelli G., Romagnani P., Anders H.J., Anguiano L.
  
• Lupus nephritis. Nature Reviews Disease Primers, Vol. 6. 2020, Article number 7.
  Anders H.J., Saxena R., Zhao M.H., Parodis I., Salmon J.E., Mohan C.
  
• Only hyperuricemia with crystalluria but not asymptomatic hyperuricemia drives progression of chronic kidney disease. J Am Soc Nephrol. Vol. 31. 2020, Issue 12, pp. 2773-2792 .
  Sellmayr M., Hernandez-Petzsche M.R., Ma Q., Krüger N., Liapis H., Brink A., Lenz B., Angelotti M.L., Gnemmi V., Kuppe C., Kim H., Bindels E.M.J., Taijti F., Saez-Rodriiguez, J., Lech M., Kramann R., Romagnani P., Anders H.J., Steiger S.
  
• Podocytopathies. Nature Reviews Disease Primers Vol. 6. 2020, Issue 1, Article number: 68.
  Kopp J.B., Anders H.J., Susztak K., Podesta M.A., Remuzzi G., Hildebrandt F., Romagnani P.
  
• A multicenter blinded preclinical randomized controlled trial on Jak1/2 inhibition in MRL/MpJ-Fas-lpr mice with proliferative lupus nephritis predicts low effect size. Kidney International, Vol. 99. 2021, Issue 6, pp. 1331-1341.
  Lei Y., Sehnert B., Voll R.E., Jacobs-Cachá C., Soler M.J., Sanchez-Niño M.D., Ortiz A, Bülow R.D., Boor P., Anders H.J.
  
• Acute kidney injury. Nature Reviews Disease Primers, Vol. 7. 2021, Issue 1, Article number: 52.
  Kellum J.A., Romagnani P., Ashuntantang G., Ronco C., Rarbock A., Anders H.J.
  
• Nephron overload as a therapeutic target to maximize kidney lifespan. Nature Reviews Nephrology, Vol. 18. 2022, pp. 171–183.
  Luyckx V.A., Rule A.D., Tuttle K.R., Delanaye P., Liapis H., Gandjour A., Romagnani P., Anders H.J.